ABBVIE ANNOUNCES TOPLINE RESULTS FROM THE PHASE 3 INTREPID TRIAL SHOWING LUTIKIZUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF DISEASE IN PATIENTS WITH HIDRADENITIS SUPPURATIVA

Reuters · 2d ago

Please log in to view news